Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Bousquet, Guilhem ^a,b,c   Feugeas, Jean Paul ^a,b   Ferreira, Irmine ^a,b   Vercellino, Laetitia ^a,c   Jourdan, Nathalie ^c   Bertheau, Philippe ^a,b,c   de Bazelaire, Cédric ^a,b,c   Barranger, Emmanuel ^a,d   Janin, Anne ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; MONOCLONAL ANTIBODY; PACLITAXEL; TAXOID;

ADULT; ANIMAL; CANCER TRANSPLANTATION; CASE REPORT; FEMALE; GENETICS; HUMAN; MAMMARY NEOPLASMS, ANIMAL; MOUSE; NEOPLASM METASTASIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PACLITAXEL; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84893792203     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3615     Document Type: Letter

References (5)

1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767. 10.1172/JCI45014, 3127435, 21633166.
2. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013, 19:5533-5540. 10.1158/1078-0432.CCR-13-0799, 23948975.
3. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009, 9:29-33. 10.3816/CBC.2009.n.005, 19299237.
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892. 10.1056/NEJMoa1113205, 22397650.
5. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10:1311-1316. 10.1158/1535-7163.MCT-11-0233, 21673092.